Zymeworks Inc. (ZYME)
ZYME trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$25.07
-1.03% on the day
Market cap
$1.8B
Small cap
Revenue · 2025
$106.0M
+38.9% on 2024
Net income · 2025
-$81.1M
-76.6% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | ZYME on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001937653 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $106.0M |
| Net income | -$81.1M |
| Operating income | -$92.5M |
| Net margin | -76.6% |
| Operating margin | -87.3% |
| Revenue growth | +38.9% |
| Cash | $41.2M |
| Total assets | $346.5M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 16.8× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2024-08-02 |
| Latest annual report | 10-K | 2026-03-02 |
| Latest quarterly / interim | 10-Q | 2026-08-06 |
| Latest current report | 8-K | 2026-09-23 |
| Latest proxy | DEFA14A | 2025-11-10 |
Source: SEC EDGAR submissions feed, 332 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -6.2% |
| 1 month | -4.4% |
| 3 months | +2.9% |
| Year to date | -5.5% |
| 1 year | +37.5% |
| From 52-week high | -19.8% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| AGIO | Agios Pharmaceuticals Inc. | $30.21 | -1.98% | $1.8B |
| TRVI | Trevi Therapeutics Inc. | $12.29 | -4.95% | $1.8B |
| XNCR | Xencor Inc. | $23.52 | -6.07% | $1.7B |
| SRPT | Sarepta Therapeutics Inc. Common Stock (DE) | $16.51 | -5.33% | $1.7B |
| BRVE | Braveheart Bio Inc. | $19.33 | -5.06% | $1.7B |
| BHVN | Biohaven Ltd. Common Shares | $11.42 | -3.30% | $1.7B |
| PVLA | Palvella Therapeutics Inc. | $128.51 | -4.37% | $1.9B |
| MLYS | Mineralys Therapeutics Inc. | $21.00 | -5.53% | $1.9B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier